Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Inventiva ( (IVA) ) has issued an announcement.
On July 9, 2025, Inventiva announced key leadership changes with the appointment of Jason Campagna as President of R&D and Chief Medical Officer, and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance. These appointments are part of Inventiva’s strategy to drive long-term growth and operational excellence, as the company prepares for the anticipated regulatory submissions and commercialization of lanifibranor, its treatment for MASH. The leadership transition marks a pivotal moment for Inventiva, as it aims to advance its clinical programs and achieve significant milestones in the coming years.
The most recent analyst rating on (IVA) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Inventiva stock, see the IVA Stock Forecast page.
Spark’s Take on IVA Stock
According to Spark, TipRanks’ AI Analyst, IVA is a Neutral.
Inventiva’s overall stock score is primarily impacted by its financial struggles, including continuous losses and heavy reliance on external funding. While the earnings call provided some optimism regarding clinical developments and financial stability, significant risks remain. The technical analysis and valuation further reflect a challenging outlook for potential investors.
To see Spark’s full report on IVA stock, click here.
More about Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical needs. The company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for treating adult patients with MASH. Inventiva is publicly listed on Euronext Paris and the Nasdaq Global Market.
Average Trading Volume: 21,522
Technical Sentiment Signal: Buy
Current Market Cap: $430.8M
Find detailed analytics on IVA stock on TipRanks’ Stock Analysis page.